TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer
Status:
Recruiting
Trial end date:
2022-09-17
Target enrollment:
Participant gender:
Summary
This study is to evaluate the efficacy and safety ofTCHP
(docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by
THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as
Neoadjuvant Treatment in HER2- Positive breast cancer. The endpoint of pathologic complete
response is used as a surrogate marker for survival. Safety and tolerability assessed by
number of grade 4 toxicities and hospitalizations.
Phase:
Phase 2
Details
Lead Sponsor:
Guangdong General Hospital Guangdong Provincial People's Hospital